EnoTech: Revenue reached 422 million yuan in 2025, with a year-on-year decrease of 40.84% in net profit.

Engnote announced that in 2025, the company achieved total operating revenue of 422.03 million yuan, a year-on-year decrease of 32.08%; net profit attributable to owners of the parent company was 146.04 million yuan, a year-on-year decrease of 40.84%. The decline in performance was mainly due to the impact of policies on the in vitro diagnostics industry, intensified competition in the subdivision testing field, and the prevalence of pathogens not being as favorable as in 2024. At the same time, the company's labor costs, R&D expenses, and market investment expenses have increased, leading to a greater decline in profit indicators. However, the company has made progress in research and development and marketing, laying a foundation for development in 2026.